What's Happening?
Delcath Systems, Inc., an interventional oncology company, announced its financial results for the first quarter of 2026, reporting a total revenue of $25.0 million, up from $19.8 million in the same period of 2025. The company saw significant growth
in its HEPZATO KIT™ sales, which contributed $23.3 million to the revenue, marking a substantial increase from $18.0 million in the previous year. Despite the revenue growth, Delcath reported a net loss of $1.1 million, contrasting with a net income of $1.1 million in the first quarter of 2025. The company also highlighted the publication of results from the CHOPIN Phase 2 trial in The Lancet Oncology, which demonstrated improved progression-free survival in metastatic uveal melanoma when combining ipilimumab and nivolumab with percutaneous hepatic perfusion. Delcath's CHEMOSAT® system was also included in the ESMO–EURACAN Clinical Practice Guideline as a recommended therapy option.
Why It's Important?
The financial results and strategic developments reported by Delcath Systems underscore the company's growing influence in the oncology sector, particularly in liver cancer treatment. The increase in HEPZATO KIT sales reflects a positive market reception and potential for further growth, which is crucial for the company's financial health and investor confidence. The inclusion of CHEMOSAT in clinical guidelines and the publication of the CHOPIN trial results enhance Delcath's credibility and could lead to increased adoption of its therapies. This progress is significant for stakeholders, including patients who may benefit from improved treatment options, and investors looking for growth opportunities in the biotech sector.
What's Next?
Delcath Systems has set a revenue guidance of at least $100 million for 2026, with expectations of continued growth in HEPZATO KIT sales. The company plans to maintain gross margins between 84% and 87% and achieve positive adjusted EBITDA. These targets suggest a strategic focus on expanding market share and improving financial performance. Delcath's ongoing clinical trials and commercial expansion activities will be critical in achieving these goals. The company's ability to manage its supply chain and secure necessary regulatory approvals will also play a vital role in its future success.
